Evidence map›Paper›PMID 33666893›Full record

ArticleRheumatology and therapy2021

Risk Factors for Progression from Subclinical to Clinical Phase of Psoriatic Arthritis: A Case-Control Study.

Yiyi Wang, Li Ding, Jihui Chen, Lingyan Zhang, Min Yang, Zhibin Liu, Liangliang Cheng, Tianjiao Lan, Gaojie Li, Yuanxia Gu and 2 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Yiyi Wang *Department of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Li Ding *Department of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jihui Chen *Department of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Lingyan ZhangDepartment of Ultrasound & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Min YangDepartment of Rheumatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zhibin LiuFaculty of Medicine, Macau University of Science and Technology, Macau, China.
Liangliang ChengSchool of Public Health, Sun Yat-Sen University, Guangzhou, Guangdong, China.
Tianjiao LanChina School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.
Gaojie LiDepartment of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yuanxia GuDepartment of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yi LiuDepartment of Rheumatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. yi2006liu@163.com.
Wei LiDepartment of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. liweihx_hxyy@scu.edu.cn.ORCID http://orcid.org/0000-0002-9585-2884
Sichuan University · CNMacau University of Science and Technology · MOSun Yat-sen University · CN

Funding

West China Hospital, Sichuan University (CN) ZYJC18003West China Precision Medicine Industrial Technology Institutes 2018-CY02-00058-GX
6 · The paper itself

Abstract

introductionThe objective of this study is to identify the potential risk factors for progression from subclinical to clinical psoriatic arthritis (PsA).

methodsA retrospective, longitudinal, case-control study was conducted at a single hospital, including 25 patients with clinically confirmed PsA in the case group and 137 controls without confirmed PsA. All patients in both groups had a medical history of subclinical PsA. Various baseline covariates were collected from all patients when they had a status of subclinical PsA. Univariate, multivariate, stratified, and interaction analyses were employed to identify potential risk factors of transiting to clinical PsA from subclinical PsA.

resultsIn multivariate logistic regression analysis, older age (OR 10.15, 95% CI 2.79-36.91, p = 0.00), alcohol drinking (OR 3.43, 95% CI 1.17-10.12, p = 0.03), elevated high-sensitivity C-reactive protein (hs-CRP) (OR 1.05, 95% CI 1.01-1.09, p = 0.03) were identified as risk factors for transition from subclinical to clinical PsA. Stratified and logistic regression analyses suggest a significant interaction between age and fatty liver. For patients aged less than 45 years old, the association between fatty liver and clinical PsA was statistically significant.

conclusionsOlder age, alcohol drinking, elevated hs-CRP, and the presence of fatty liver at less than 45 years old appear to increase the risk of transition from subclinical to clinical PsA. These findings call for a need to manage these risk factors.

Indexed as

Disease progressionPsoriatic arthritisRisk factors

Identifiers

PMID33666893
PMCPMC7990990
OpenAlexW3205894918

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.